Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Blocking the MDM2/X-P53 protein-protein interaction has been widely recognized as an attractive therapeutic strategy for the treatment of cancers. Numerous small-molecule MDM2 inhibitors have been reported since the release of the structure of the MDM2-P53 interaction in 1996, SAR405838, NVP-CGM097,...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2020-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|